NCT02297178

Brief Summary

Urinary incontinences is a highly prevalent and distressing condition which has a significant impact on health related quality of life in millions of women worldwide. Of all women with incontinence, 90% will have overactive bladder symptoms (OAB), and 50% will have detrusor overactivity (DO) on cystometry. The overactive bladder syndrome is defined by the International Continence society as "Urinary urgency, with or without urge incontinence, usually with frequency and nocturia if there is a no infection or proven pathology" (Abrams et al 2002) Initial management of OAB and DO consists of conservative measures such as altering fluid intake, bladder retraining and drug therapy. The next step consists of interventions such as cystoscopy and urethral dilatation, on the basis that it will allow intrinsic bladder problems such as interstitial cystitis to excluded, excluded, and may confer a symptomatic benefit. The original study showed no benefit of urethral dilatation versus no dilatation at 6 months follow up (Duckett 2007). The investigators do not know the natural history of patients with voiding dysfunction. Therefore reviewing their symptoms will give a better idea of what happens to these patients symptoms over time.

Trial Health

15
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Aug 2016

Shorter than P25 for all trials

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 11, 2014

Completed
10 days until next milestone

First Posted

Study publicly available on registry

November 21, 2014

Completed
1.7 years until next milestone

Study Start

First participant enrolled

August 1, 2016

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2016

Completed
Last Updated

October 17, 2016

Status Verified

October 1, 2016

Enrollment Period

4 months

First QC Date

November 11, 2014

Last Update Submit

October 13, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • ICIQ-Fluts questionnaire

    To identify if there is any long term benefit from urethral dilatation over cystoscopy alone. Their baseline symptoms will be assessed and compared to those identified at baseline in the previous study.

    3 years

Secondary Outcomes (3)

  • King's Health Questionnaire

    3 years

  • Urgency Perception Scale Questionnaire

    3 years

  • Uroflowmetry

    3 years

Study Arms (2)

Cystoscopy Alone

Patients who received cystoscopy only for treatment of OAB and voiding dysfunction.

Procedure: Cystoscopy only

Cystoscopy & Urethral Dilatation

Patients who received urethral dilatation and cystoscopy for treatment of OAB and voiding dysfunction.

Procedure: Cystoscopy and Urethral dilatation

Interventions

Cystoscopy performed for investigation and treatment of OAB and voiding dysfunction

Cystoscopy Alone

Cystoscopy and urethral dilatation performed for investigation and treatment of OAB and voiding dysfunction

Cystoscopy & Urethral Dilatation

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Entry to the study will be offered to all women previously recruited into the original randomised controlled trial. This study is a 3 year follow up of a randomised controlled trial. Patients will be sent a letter offering a review appointment.

You may qualify if:

  • Significant Overactive Bladder Symptoms
  • Based on scoring 1 or 2 on the Urgency Perception Scale
  • On the symptoms domain of the KHQ
  • More than 8 voids per day on frequency volume chart +/- 2 or more episodes of nocturia
  • Pressure flow studies demonstrate a maximum flow rate of less than 15ml on a minimum voided volume of 200ml with a high or normal detrusor pressure at maximum flow or post-void residual of 200ml or over
  • Patients must be able to give informed consent for the study.

You may not qualify if:

  • Presence of concurrent urodynamic stress incontinence.
  • Patients with bladder pathology or haematuria of unknown origin.
  • Patients with neurological disorders (as these may affect voiding).
  • Symptomatic pelvic organ prolapse requiring intervention
  • Patients with bladder pathology (including urinary tract infection) or haematuria of unknown origin

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (3)

  • Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A; Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167-78. doi: 10.1002/nau.10052. No abstract available.

  • Duckett JR, Basu M. The predictive value of preoperative pressure-flow studies in the resolution of detrusor overactivity and overactive bladder after tension-free vaginal tape insertion. BJU Int. 2007 Jun;99(6):1439-42. doi: 10.1111/j.1464-410X.2007.06842.x. Epub 2007 Apr 5.

  • Masarani M, Willis RG. Urethral dilatation in women: urologists' practice patterns in the UK. Ann R Coll Surg Engl. 2006 Sep;88(5):496-8. doi: 10.1308/003588406X114884.

MeSH Terms

Conditions

Urinary Bladder, OveractiveUrinary Incontinence

Interventions

Cystoscopy

Condition Hierarchy (Ancestors)

Urinary Bladder DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesLower Urinary Tract SymptomsUrological ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsUrination Disorders

Intervention Hierarchy (Ancestors)

EndoscopyDiagnostic Techniques, SurgicalDiagnostic Techniques and ProceduresDiagnosisDiagnostic Techniques, UrologicalMinimally Invasive Surgical ProceduresSurgical Procedures, OperativeUrologic Surgical ProceduresUrogenital Surgical Procedures

Study Officials

  • Jonathan RA Duckett, FRCOG, MBChB

    Medway Maritime Hospital

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Consultant Gynaecologist and Obstetrician

Study Record Dates

First Submitted

November 11, 2014

First Posted

November 21, 2014

Study Start

August 1, 2016

Primary Completion

December 1, 2016

Study Completion

December 1, 2016

Last Updated

October 17, 2016

Record last verified: 2016-10